Company news
Creative Medical Technology Holdings, Inc. news in 2021
Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2021, newest first.
Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market
December 2, 2021
Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market
November 8, 2021
Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product
October 11, 2021
Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz™ Platform
September 30, 2021
Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem®
September 15, 2021
Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors
August 8, 2021
Creative Medical Technology Holdings Announces MyeloCelz™ The Company's Second Regenerative Immunotherapy Product
July 19, 2021
Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance
June 21, 2021
Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference
June 16, 2021
Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes
June 8, 2021
Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease
May 23, 2021
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke Treatment
May 13, 2021
Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine
March 22, 2021
Creative Medical Technology Holdings, Inc. Announces FDA Acknowledgment of IND Application for ImmCelz® to Treat Stroke
March 15, 2021
Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites
March 9, 2021
Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy
March 3, 2021
Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application
March 2, 2021
Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®
February 15, 2021
Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem® Female Infertility/Ovarian Failure Treatment
February 9, 2021
Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board
February 7, 2021
Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity
January 31, 2021
Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz® Through FDA
January 20, 2021
Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes
January 18, 2021
Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy
January 11, 2021
ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients
January 5, 2021